Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares August 2, 2021
Cell analysis instruments provider Cytek BioSciences prices upsized IPO at $17 midpoint July 24, 2021
Boston Scientific shells out a hearty $295M for Farapulse’s electric-field-generating afib treatment June 24, 2021
Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases June 23, 2021
Singular Genomics Systems, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock May 26, 2021
FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation March 3, 2021
Farapulse Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation January 29, 2021
Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc. September 21, 2020